- Home
- ASBP vs EDSA Comparison
ASBP vs EDSA Comparison
Compare ASBP & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASBP
- EDSA
- Stock Information
- Founded
- ASBP 2021
- EDSA 2015
- Country
- ASBP United States
- EDSA Canada
- Employees
- ASBP N/A
- EDSA N/A
- Industry
- ASBP Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- ASBP Health Care
- EDSA Health Care
- Exchange
- ASBP Nasdaq
- EDSA Nasdaq
- Market Cap
- ASBP 18.7M
- EDSA 18.6M
- IPO Year
- ASBP N/A
- EDSA N/A
- Fundamental
- Price
- ASBP $0.33
- EDSA $2.46
- Analyst Decision
- ASBP
- EDSA Strong Buy
- Analyst Count
- ASBP 0
- EDSA 2
- Target Price
- ASBP N/A
- EDSA $13.00
- AVG Volume (30 Days)
- ASBP 40.8M
- EDSA 135.9K
- Earning Date
- ASBP 11-24-2025
- EDSA 08-08-2025
- Dividend Yield
- ASBP N/A
- EDSA N/A
- EPS Growth
- ASBP N/A
- EDSA N/A
- EPS
- ASBP N/A
- EDSA N/A
- Revenue
- ASBP N/A
- EDSA N/A
- Revenue This Year
- ASBP N/A
- EDSA N/A
- Revenue Next Year
- ASBP N/A
- EDSA N/A
- P/E Ratio
- ASBP N/A
- EDSA N/A
- Revenue Growth
- ASBP N/A
- EDSA N/A
- 52 Week Low
- ASBP $0.20
- EDSA $1.55
- 52 Week High
- ASBP $15.80
- EDSA $4.49
- Technical
- Relative Strength Index (RSI)
- ASBP 43.96
- EDSA 47.52
- Support Level
- ASBP $0.31
- EDSA $2.42
- Resistance Level
- ASBP $0.37
- EDSA $2.90
- Average True Range (ATR)
- ASBP 0.06
- EDSA 0.23
- MACD
- ASBP 0.00
- EDSA -0.02
- Stochastic Oscillator
- ASBP 47.29
- EDSA 26.45
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.